Search This Blog

Sunday, October 9, 2016

New Data on the Combination of Lilly's ALIMTA® (pemetrexed) and Merck's KEYTRUDA® (pembrolizumab) Show a Near-Doubling of Objective Response Rate Compared to Standard of Care Alone in First-Line Metastatic Non-Small Cell Lung Cancer (NYSE:LLY)

INDIANAPOLISOct. 9, 2016 /PRNewswire/ -- Important clinical study results from one of Eli Lilly and Company's (NYSE: LLY) ongoing immuno-oncology collaborations with Merck (known as MSD outside the U.S. and Canada) were announced today at the ESMO 2016 Congress, the annual meeting of the European Society for Medical Oncology. Specifically, data released from KEYNOTE-021, Cohort G, which evaluated ALIMTA® (pemetrexed) plus carboplatin in combination with Merck's KEYTRUDA® (pembrolizumab) in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC), showed that the combination of ALIMTA, KEYTRUDA and carboplatin demonstrated superior efficacy compared to ALIMTA and carboplatin - standard of care - alone.



New Data on the Combination of Lilly's ALIMTA® (pemetrexed) and Merck's KEYTRUDA® (pembrolizumab) Show a Near-Doubling of Objective Response Rate Compared to Standard of Care Alone in First-Line Metastatic Non-Small Cell Lung Cancer (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.